Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC ILOC phase II study of durvalumab + tremelimumab with local ablation or stereotactic radiotherapy in colorectal cancer liver metastases
NL-OMON55697Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in colorectal cancer (CRC), colorectal cancer liver metastasis (CRLM), sponsored by European Organisation for Research and Treatment of Cancer. Started May 2019; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON55697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55697.